Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets.

There are numerous studies on the immune response against malignant human tumors. This study was aimed to address the complexity and specificity of humoral immune response against a benign human tumor. We assembled a panel of 62 meningioma-expressed antigens that show reactivity with serum antibodies of meningioma patients, including 41 previously uncharacterized antigens by screening of a fetal brain expression library. We tested the panel for reactivity with 48 sera, including sera of patients with common-type, atypical, and anaplastic meningioma, respectively. Meningioma sera detected an average of 14.6 antigens per serum and normal sera an average of 7.8 antigens per serum (P = 0.0001). We found a decline of seroreactivity with malignancy with a statistical significant difference between common-type and anaplastic meningioma (P < 0.05). We detected 17 antigens exclusively with patient sera, including 12 sera that were reactive against KIAA1344, 9 against natural killer tumor recognition (NKTR), and 7 against SRY (sex determining region Y)-box2 (SOX2). More than 80% of meningioma patients had antibodies against at least one of the antigens KIAA1344, SC65, SOX2, and C6orf153. Our results show a highly complex but specific humoral immune response against a benign tumor with a distinct serum reactivity pattern and a decline of complexity with malignancy. The frequent antibody response against specific antigens offers new diagnostic and therapeutic targets for meningioma. We developed a statistical learning method to differentiate sera of meningioma patients from sera of healthy donors.

[1]  E. Meese,et al.  Novel immunogenic antigen homologous to hyaluronidase in meningioma. , 1998, Human molecular genetics.

[2]  M. Buschle,et al.  PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome , 2004, International journal of cancer.

[3]  E. Meese,et al.  Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a beta-N-acetylglucosaminidase. , 2001, Biochemical and biophysical research communications.

[4]  S. J. Monahan,et al.  Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. , 2002, Biochemical and biophysical research communications.

[5]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[6]  E. Meese,et al.  Role of amplified genes in the production of autoantibodies. , 1999 .

[7]  E. Hedley‐Whyte,et al.  Progesterone and estrogen receptors in meningiomas: prognostic considerations. , 1997, Journal of neurosurgery.

[8]  M J O'Hare,et al.  Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. , 2001, Cancer immunity.

[9]  G. Kispál,et al.  Molecular Cloning and Immunologic Characterization of a Novel cDNA Coding for Progesterone-Induced Blocking Factor 1 , 2003, The Journal of Immunology.

[10]  E. Chan,et al.  cDNA cloning and characterization of a novel nucleolar protein. , 1996, Molecular biology of the cell.

[11]  M. Schummer,et al.  Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q , 2003, International journal of cancer.

[12]  W. Nastainczyk,et al.  MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies , 2002, Oncogene.

[13]  A. Rosen,et al.  Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status , 1999, The Journal of experimental medicine.

[14]  K. Zang,et al.  Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases , 2001, Cytogenetic and Genome Research.

[15]  Christina Backes,et al.  GraBCas: a bioinformatics tool for score-based prediction of Caspase- and Granzyme B-cleavage sites in protein sequences , 2005, Nucleic Acids Res..

[16]  U. Fischer,et al.  cDNA cloning and chromosomal mapping of a predicted coiled-coil proline-rich protein immunogenic in meningioma patients. , 1997, Human molecular genetics.

[17]  D. Jäger,et al.  Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Y. Eishi,et al.  Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. , 2004, International journal of oncology.

[19]  R. Wellenreuther,et al.  Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. , 1995, Cancer research.

[20]  N. Thornberry,et al.  A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B , 1997, The Journal of Biological Chemistry.

[21]  J. Roder,et al.  A cyclophilin-related protein involved in the function of natural killer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Lenartz,et al.  Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. , 1995, The American journal of pathology.

[23]  E. Meese,et al.  Loss of heterozygosity and the origin of meningioma , 1987, Human Genetics.

[24]  A. Lupas,et al.  Long charge-rich alpha-helices in systemic autoantigens. , 1993, Biochemical and Biophysical Research Communications - BBRC.

[25]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[26]  M. Wolter,et al.  Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Olivier Delattre,et al.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas , 1994, Nature Genetics.

[29]  B. Scheithauer,et al.  Merlin, DAL‐1, and Progesterone Receptor Expression in Clinicopathologic Subsets of Meningioma: A Correlative Immunohistochemical Study of 175 Cases , 2000, Journal of neuropathology and experimental neurology.

[30]  M. Wegner,et al.  From head to toes: the multiple facets of Sox proteins. , 1999, Nucleic acids research.

[31]  H. Schreiber,et al.  Immunodominance and tumor escape. , 2002, Seminars in cancer biology.

[32]  Masahiro Toda,et al.  Identification of a human glioma antigen, SOX6, recognized by patients' sera , 2004, Oncogene.

[33]  V. P. Collins,et al.  Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. , 1990, Cancer research.

[34]  E. Meese,et al.  Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.